comparemela.com

Latest Breaking News On - Heidelberg pharmaceuticals - Page 1 : comparemela.com

RedHill and U S Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

RedHill and U S Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

RedHill Biopharma : and U S Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola - Form 6-K -December 20, 2023 at 08:58 am EST

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.

RedHill s RHB-107 Included in U S Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funde

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.